Literature DB >> 3546575

Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).

L S McDaniel, J Yother, M Vijayakumar, L McGarry, W R Guild, D E Briles.   

Abstract

PspA is a cell surface protein of Streptococcus pneumoniae that is present on a number of clinical isolates as well as the nonencapsulated laboratory strain Rx1. In a previous report we have shown that mAbs directed against PspA can protect mice from at least some of the pneumococcal strains bearing this protein. In our present report we have produced insertional inactivation mutants that lack PspA and have used these mutants to demonstrate that PspA can play a role in pneumococcal virulence and that anti-PspA immunity can lead to protection against pneumococcal infection. PspA- mutants were obtained using derivatives of plasmid pVA891 carrying chromosomal fragments from Rx1. From one of the mutants, we cloned a 550 bp fragment of the pneumococcal gene into pVA891 and transferred this chimeric plasmid, designated pKSD300, into Escherichia coli. After transformation of pKSD300 into Rx1, PspA production is not detected. In colony hybridization experiments, the 550 bp fragment hybridizes specifically to pneumococcal isolates in a pattern consistent with the hypothesis that the fragment is a portion of the pspA structural gene that is different from the portions coding for the antigenic determinants detected by mAbs Xi64 or Xi126. When X-linked immunodeficient (xid) CBA/N mice were immunized with wild-type Rx1, they were resistant to challenge with type 3 strain WU2. However, when these mice were immunized with a PspA- mutant of Rx1, they failed to survive the subsequent challenge, indicating that immunity to PspA can contribute to the resistance to pneumococcal infection. Using pKSD300 we insertionally inactivated pspA in D39, a virulent strain of S. pneumoniae. When injected intravenously there was a 10-fold greater reduction of the mutant pneumococci in the blood, as compared to the wild-type D39.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3546575      PMCID: PMC2188511          DOI: 10.1084/jem.165.2.381

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III.

Authors:  O T Avery; C M Macleod; M McCarty
Journal:  J Exp Med       Date:  1944-02-01       Impact factor: 14.307

2.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation.

Authors:  N B Shoemaker; W R Guild
Journal:  Mol Gen Genet       Date:  1974

5.  Cloning and physical characterization of chromosomal conjugative elements in streptococci.

Authors:  M N Vijayakumar; S D Priebe; G Pozzi; J M Hageman; W R Guild
Journal:  J Bacteriol       Date:  1986-06       Impact factor: 3.490

6.  A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots.

Authors:  M S Blake; K H Johnston; G J Russell-Jones; E C Gotschlich
Journal:  Anal Biochem       Date:  1984-01       Impact factor: 3.365

7.  Studies on transformation of Escherichia coli with plasmids.

Authors:  D Hanahan
Journal:  J Mol Biol       Date:  1983-06-05       Impact factor: 5.469

8.  Novel shuttle plasmid vehicles for Escherichia-Streptococcus transgeneric cloning.

Authors:  F L Macrina; R P Evans; J A Tobian; D L Hartley; D B Clewell; K R Jones
Journal:  Gene       Date:  1983-11       Impact factor: 3.688

9.  IMMUNIZATION OF EXPERIMENTAL ANIMALS WITH A SOLUBLE ANTIGEN EXTRACTED FROM PNEUMOCOCCI.

Authors:  R J Dubos
Journal:  J Exp Med       Date:  1938-04-30       Impact factor: 14.307

10.  ACTIVE AND PASSIVE IMMUNITY TO PNEUMOCOCCUS INFECTION INDUCED IN RABBITS BY IMMUNIZATION WITH R PNEUMOCOCCI.

Authors:  W S Tillett
Journal:  J Exp Med       Date:  1928-11-30       Impact factor: 14.307

View more
  83 in total

1.  The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin.

Authors:  P Balachandran; S K Hollingshead; J C Paton; D E Briles
Journal:  J Bacteriol       Date:  2001-05       Impact factor: 3.490

2.  Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Authors:  A H Tu; R L Fulgham; M A McCrory; D E Briles; A J Szalai
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

5.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

6.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 7.  Molecular biology and respiratory disease. 6. Modern molecular biology and respiratory bacterial infections: a revolution on the horizon.

Authors:  T F Murphy
Journal:  Thorax       Date:  1990-07       Impact factor: 9.139

8.  Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Authors:  Bing Ren; Alexander J Szalai; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

10.  Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

Authors:  S Langermann; S R Palaszynski; J E Burlein; S Koenig; M S Hanson; D E Briles; C K Stover
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.